PIK3CG and neoplasm: The CMAP analysis of the RNA-seq signature with LINCS CP signatures (Fig. 6) shows that treating several different cancer cell lines with inhibitors of PI3K, mTOR, CDK, and inhibitors of some other more generic proliferation targets (e.g., TOP21, AURKA) (see Supplemental Data SD3 for complete results) produces signatures that are positively correlated with RNA-seq Luminal A vs Her2E signature, suggesting that such treatments may counteract the Her2E tumor driving events.